Anavex Life Sciences Corp (AVXL)

[12x]

Congrats to Team Anavex for achieving this critical milestone on time! The expanded leadership team is executing exceptionally well.

Next up: OLE interim results, which will likely give us a clearer picture of the MAA's approval prospects, including any potential conditions.

Dr. Lopez-Talavera seems to be steering the team toward the next goals, including worldwide filings (FDA next?) and positioning blarcamesine as both a complementary and alternative therapy to current MAbs—potentially addressing 100% of Alzheimer's patients.

“This MAA submission is the first for oral blarcamesine as we are requesting a review of the Marketing Authorization Application with the aim to move closer to bringing this therapy to patients with Alzheimer’s disease worldwide,” said Juan Carlos Lopez-Talavera, MD, PhD, Head of Research and Development of Anavex. “Blarcamesine’s safety and efficacy profile could represent a novel treatment that could be complementary or an alternative to anti-beta amyloid monoclonal antibody drugs.”